hero image

Biogen to Present at the Goldman Sachs Alzheimer’s Symposium

March 28, 2016 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Goldman Sachs Alzheimer’s Symposium. The webcast will be live on Monday, April 11, 2016 at 12:20p.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of the webcast will be available for 14 days following the presentation.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.

 

Contact:

Biogen
Karen Jewell, 781-464-2442
Investor Relations

thumb
January 26, 2023
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines

thumb
January 18, 2023
BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS FEBRUARY 15, 2023

Cambridge, Mass.— Biogen Inc . (Nasdaq:BIIB) today announced it will report fourth quarter and full year 2022 financial results Wednesday, February 15, 2023, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at